Peptide therapy TikTok claims: what the science actually supports

What did @rosiemontalbano1 actually say?

The creator offered five beginner tips for what she called "respiratory tired" — almost certainly a garbled transcription of "semaglutide" or a similar GLP-1 receptor agonist, though the video is tagged under peptide therapy. She told viewers to start low on dose, stay consistent, drink a lot of water, stop if something feels wrong, and be patient with results. No specific doses, compounds, or conditions were named by her directly.

The advice is general enough that it could apply to almost any peptide protocol. That vagueness is both its strength and its weakness. Viewers looking for real guidance on, say, BPC-157 or ipamorelin are going to walk away with motivational content, not clinical information. That said, the core message — go slow, stay hydrated, trust your body over social pressure — is not harmful on its face.

Does the science back this up?

Partially, yes. The hydration advice has real clinical grounding, especially in the context of GLP-1 therapy. The titration advice ("start the dose low") is standard prescribing practice. But some claims are oversimplified to the point of being misleading.

On hydration: GLP-1 receptor agonists like semaglutide are associated with nausea, vomiting, and reduced appetite, all of which increase dehydration risk. Davies et al. (2021, New England Journal of Medicine) documented gastrointestinal side effects as the most common adverse events in the STEP trials, and dehydration is a documented downstream risk. So yes, hydration matters. But framing it as "literally the most important part" overstates the case. Electrolyte balance, protein intake, and regular clinical monitoring matter just as much, arguably more over the long term.

On low-and-slow titration: FDA-approved protocols for semaglutide explicitly use dose escalation schedules spanning months. Wilding et al. (2021, NEJM) confirmed that gradual titration reduces GI side effects. The creator is right here, even if she doesn't cite the evidence.

What did they get wrong (or right)?

Let's give credit where it's due. "If something feels off in your body, don't just ignore it just because people are telling you to keep going" is genuinely good advice and something a lot of wellness influencers actively avoid saying. That's a point in her favor.

What she got wrong, or at least incomplete: consistency advice is fine, but she says "don't keep up in the dose every week and expect instant results" without explaining what realistic timelines actually look like. The STEP 1 trial (Wilding et al., 2021) showed meaningful weight outcomes at 68 weeks. Viewers with no clinical context might interpret "gradual" as weeks, when the data suggests months to over a year.

The hydration framing is also overblown. Saying you need to drink water "like your life literally depends on it" could push people toward overhydration, which carries its own risks including hyponatremia, particularly in people with kidney or cardiac conditions. Clinical guidance recommends adequate hydration, not extreme hydration.

The transcript is also frustratingly vague about what compound she's actually discussing. Peptide therapy is a broad category. BPC-157, TB-500, and GLP-1 peptides have very different mechanisms, risk profiles, and evidence bases. Giving blanket beginner tips that skip over which peptide you're even using is a real limitation of this content.

What should you actually know?

If you are starting any peptide therapy, the single most important thing this video does not tell you is to do it under medical supervision. Compounded peptides in particular exist in a regulatory gray zone. Many are not FDA-approved for the indications being discussed on social media. Dosing, purity, and administration protocols vary significantly depending on the compound.

Hydration is important, but "drink water like your life depends on it" is not a clinical instruction. Talk to a provider about your specific hydration targets, especially if you have underlying conditions. The titration advice (start low) is sound and matches clinical guidelines, but "low" means something specific in a prescriber's chart and something vague on TikTok.

Patience is genuinely warranted. Most outcome data for peptide-adjacent therapies comes from trials lasting 52 to 68 weeks or more. Anyone promising you results in a few weeks is selling something. The creator is right that results take time, even if she doesn't explain why or by how much.

• Always confirm the specific compound, source, and dosing with a licensed provider before starting.
• Side effects are real, as she says. Know what to watch for based on your specific peptide, not generic advice.
• "Gradual results" in clinical trials often means 6 to 18 months, not 6 to 8 weeks.